Study to Evaluate the Safety and Dose-Range of Navarixin (SCH 527123, MK-7123) in Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (MK-7123-012)

NCT00441701 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

99

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

DRUG: Navarixin 1 mg
DRUG: Navarixin 10 mg
DRUG: Placebo to match navarixin
DRUG: Rescue medication

Sponsor

Merck Sharp & Dohme LLC